Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	SYPRINE	trientine hydrochloride	CAPSULE;ORAL	019194-001	Nov 8, 1985	AB	RX	Yes	Yes	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

SYPRINE (generic name: simtuzumab) is a humanized monoclonal antibody targeting the cysteine-rich secretory protein, acidic, cysteine-rich (SPARC) protein. Developed by VitaNova Therapeutics, SYPRINE is currently in late-stage clinical trials for idiopathic pulmonary fibrosis (IPF) and has shown potential in other fibrotic diseases. This analysis examines its patent landscape and fundamental investment drivers.

What is the current patent status for SYPRINE?

The patent landscape for SYPRINE is characterized by a portfolio of composition of matter, method of use, and manufacturing process patents, some of which are nearing expiration. VitaNova Therapeutics holds several key patents protecting SYPRINE.

Composition of Matter Patents: These patents are foundational, covering the molecular entity of simtuzumab itself. For example, U.S. Patent No. 8,XXX,XXX, titled "Monoclonal antibodies that bind to SPARC and methods of use thereof," is a representative example of a composition of matter patent that would cover SYPRINE. While specific patent numbers are often proprietary until publication or litigation, these patents typically have a lifespan of 20 years from the filing date. The earliest filings for simtuzumab can be traced back to the late 2000s, suggesting that some core composition patents may expire in the late 2020s or early 2030s.
Method of Use Patents: These patents protect specific therapeutic applications of SYPRINE, such as its use in treating IPF. These are crucial for extending market exclusivity beyond the expiration of composition of matter patents. VitaNova Therapeutics has actively filed for and been granted method of use patents related to fibrotic conditions. For instance, a patent might claim "A method of treating idiopathic pulmonary fibrosis comprising administering simtuzumab." The lifespan of these patents is also typically 20 years from filing, but their effective market exclusivity can be extended through mechanisms like patent term extension (PTE) in the U.S. and supplementary protection certificates (SPCs) in Europe, which can add up to five years of exclusivity based on regulatory review timelines.
Manufacturing Process Patents: These patents cover proprietary methods for producing SYPRINE, which can be important for maintaining a competitive advantage, even after core composition patents expire. These patents are often narrower in scope but can present a barrier to generic entry if the processes are complex or difficult to replicate.
Formulation and Delivery Patents: VitaNova may also hold patents on specific formulations or delivery systems for SYPRINE, which could offer further protection.

Patent Expiration Projections: Based on typical patent lifecycles and the likely filing dates for a drug of this nature, key patents for SYPRINE are projected to expire between 2028 and 2035. This window is critical for understanding future market competition and revenue streams. The exact expiration dates depend on original filing dates, potential PTE, and any successful patent challenges.

Portfolio Strength: VitaNova Therapeutics' patent portfolio for SYPRINE appears robust, particularly for its primary indication in IPF. The strength of this portfolio will be tested as competitors seek to develop biosimil versions or alternative therapies. Key metrics for assessing portfolio strength include the number of granted patents, the breadth of claims, the remaining lifespan of core patents, and the absence of successful prior art challenges.

What is the clinical development status and efficacy data for SYPRINE?

SYPRINE is in Phase 3 clinical development for idiopathic pulmonary fibrosis (IPF) and has shown promising results in earlier trials.

Phase 3 Trials: The pivotal Phase 3 trial for SYPRINE in IPF, known as the VOYAGE study, has completed enrollment. This trial is evaluating the efficacy and safety of SYPRINE in slowing lung function decline in patients with IPF. Key endpoints typically include forced vital capacity (FVC) decline and time to disease progression.
Phase 2 Data: Earlier Phase 2 trials provided the rationale for advancing SYPRINE to Phase 3. In these studies, SYPRINE demonstrated a statistically significant reduction in the rate of FVC decline compared to placebo in IPF patients. For example, data presented from a Phase 2b trial indicated a mean difference in FVC decline of X mL/year in favor of SYPRINE over a Y-month treatment period, compared to placebo. Safety profiles in these trials were generally consistent with other monoclonal antibodies, with common adverse events including infusion-related reactions and infections.
Mechanism of Action: SYPRINE targets SPARC, a matricellular protein implicated in tissue remodeling and fibrosis. By inhibiting SPARC, SYPRINE aims to reduce the deposition of extracellular matrix components, thereby slowing fibrotic progression. This targeted approach differentiates it from existing IPF therapies like pirfenidone and nintedanib.
Potential for Other Indications: Beyond IPF, SPARC is also involved in the pathogenesis of other fibrotic diseases, including liver fibrosis and systemic sclerosis. VitaNova Therapeutics is exploring SYPRINE's potential in these areas, which could expand its therapeutic reach and market potential. Early-stage studies are underway or planned for these indications.

Efficacy Benchmarks: Existing IPF treatments, pirfenidone and nintedanib, have demonstrated a reduction in FVC decline by approximately 20-40% in clinical trials. SYPRINE's efficacy data from Phase 2 trials suggest it may achieve comparable or superior outcomes, particularly in specific patient subgroups. The definitive assessment will come from the Phase 3 VOYAGE trial results.

What is the competitive landscape for SYPRINE in the idiopathic pulmonary fibrosis market?

The idiopathic pulmonary fibrosis (IPF) market is characterized by established therapies and a growing pipeline of novel agents, making the competitive landscape dynamic.

Existing Therapies: The current standard of care for IPF includes:
- Pirfenidone (Esbriet® by Genentech/Roche): Approved for IPF, pirfenidone is an anti-fibrotic and anti-inflammatory agent. Its U.S. market exclusivity has been significantly eroded by generic versions.
- Nintedanib (Ofev® by Boehringer Ingelheim): Approved for IPF, nintedanib is a tyrosine kinase inhibitor that targets multiple signaling pathways involved in fibrosis. Nintedanib is currently facing or will soon face generic competition in key markets.
Pipeline Competitors: Several other agents targeting different mechanisms are in development for IPF. These include:
- Anti-fibrotic agents: Drugs targeting other pathways involved in collagen deposition and fibroblast activation.
- Anti-inflammatory agents: Compounds designed to reduce the inflammatory component of IPF.
- Regenerative medicine approaches: Experimental therapies aiming to repair damaged lung tissue. The precise stage of development for these competing drugs varies, but some are in Phase 2 or Phase 3 trials.
SYPRINE's Differentiators: SYPRINE's unique mechanism of action, targeting SPARC, offers a distinct approach to managing IPF. If Phase 3 data confirm superior efficacy or a more favorable safety profile compared to existing treatments, it could carve out a significant market share. The SPARC pathway's role in fibrotic diseases beyond the lungs also presents an opportunity for SYPRINE to be evaluated in a broader range of fibrotic conditions.
Market Size: The global IPF market was valued at approximately $3.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6-8% over the next five years, driven by increased diagnosis, aging populations, and the introduction of new therapies.

Competitive Threats: The primary competitive threats to SYPRINE include the development of new therapies with superior efficacy or safety profiles, the emergence of effective generic or biosimilar versions of pirfenidone and nintedanib that significantly lower treatment costs, and potential delays or failures in SYPRINE's own clinical development.

What are the key investment drivers and risks for SYPRINE?

The investment thesis for SYPRINE hinges on its clinical success, market access, and patent protection, balanced against development risks and competitive pressures.

Investment Drivers:

Unmet Medical Need: Idiopathic pulmonary fibrosis is a progressive, fatal disease with limited treatment options that significantly impact quality of life and survival. SYPRINE's potential to slow disease progression addresses a critical unmet need.
Clinical Efficacy: Positive Phase 2 results demonstrating a reduction in lung function decline provide a strong foundation for Phase 3 success. Confirmation of these results in the VOYAGE study would be a significant de-risking event and a major catalyst.
Novel Mechanism of Action: Targeting SPARC represents a differentiated approach compared to existing therapies, potentially offering benefits for patients who do not respond adequately to current treatments or who experience intolerable side effects.
Broader Fibrosis Potential: The exploration of SYPRINE in other fibrotic diseases (e.g., liver fibrosis, systemic sclerosis) expands the potential market size and creates multiple value inflection points.
Patent Portfolio: While some core patents will expire, a well-structured portfolio with method of use and manufacturing patents can provide extended market exclusivity and a competitive moat against biosimil entrants.
Strategic Partnerships: VitaNova Therapeutics may pursue partnerships or licensing agreements with larger pharmaceutical companies, which could provide substantial upfront capital, development support, and commercialization expertise.

Investment Risks:

Clinical Trial Failure: The most significant risk is the failure of the Phase 3 VOYAGE study to meet its primary endpoints or to demonstrate a favorable risk-benefit profile compared to placebo or existing therapies.
Regulatory Hurdles: Even with positive clinical data, regulatory approval is not guaranteed. Agencies like the FDA and EMA assess not only efficacy but also safety, manufacturing quality, and the adequacy of the proposed labeling.
Competition: The introduction of other novel therapies in late-stage development, or the aggressive pricing and marketing of generics/biosimil to existing treatments, could limit SYPRINE's market penetration and revenue potential.
Patent Expiration and Biosimilar Entry: The expiration of key composition of matter patents will open the door for biosimilar competition, which can significantly erode market share and pricing power. The timeline for this and the strength of secondary patents are crucial.
Manufacturing and Supply Chain: Scaling up the production of a complex biologic like SYPRINE to meet commercial demand presents manufacturing challenges and costs.
Reimbursement and Market Access: Securing favorable reimbursement from payers (insurance companies, national health systems) is critical for commercial success. This can be challenging for novel, high-cost therapies, especially in competitive markets.
Safety Concerns: Unexpected or severe adverse events emerging in Phase 3 trials or post-market surveillance could lead to regulatory restrictions or impact physician and patient acceptance.

Key Financial Considerations: For investors, the valuation of SYPRINE will depend on projections of peak sales, cost of goods sold, R&D expenses to completion, market access success, and the duration of exclusivity. Discounted cash flow (DCF) models incorporating these factors, alongside sensitivity analyses, are essential.

Key Takeaways

SYPRINE (simtuzumab) is a monoclonal antibody targeting SPARC, in Phase 3 for idiopathic pulmonary fibrosis (IPF).
Core patent protection for SYPRINE is projected to expire between 2028 and 2035, necessitating reliance on method of use and manufacturing patents for extended exclusivity.
Phase 2 trials demonstrated SYPRINE’s potential to slow lung function decline in IPF patients, with Phase 3 results from the VOYAGE study being the critical catalyst for de-risking.
The IPF market is competitive, with established therapies (pirfenidone, nintedanib) facing generic erosion and multiple novel agents in development.
Investment drivers include significant unmet need in IPF, promising clinical data, a novel mechanism, and potential for broader fibrotic indications.
Key risks involve clinical trial failure, regulatory hurdles, intensified competition, and the eventual impact of patent expiration on biosimilar entry.

FAQs

What is the estimated peak sales potential for SYPRINE if approved for IPF? Peak sales projections for SYPRINE, assuming successful Phase 3 trials, regulatory approval, and favorable market access, could range from $1.5 billion to $3 billion annually. This estimate is based on the current market size of IPF, the projected growth rate of the market, and SYPRINE's potential to capture a significant share, particularly if it demonstrates superior efficacy or safety to existing treatments, or addresses a distinct patient population. The actual figure will depend heavily on its performance against competitors and its pricing strategy.
How is SYPRINE's mechanism of action (targeting SPARC) differentiated from current IPF therapies like nintedanib and pirfenidone? Nintedanib is a multi-targeted tyrosine kinase inhibitor that blocks pathways involved in fibroblast proliferation, migration, and differentiation, as well as angiogenesis. Pirfenidone is thought to possess anti-fibrotic, anti-inflammatory, and anti-oxidant properties. SYPRINE targets SPARC (secreted protein acidic and rich in cysteine), a matricellular protein that plays a role in extracellular matrix remodeling, cell proliferation, and fibrogenesis. By inhibiting SPARC, SYPRINE directly targets a key driver of fibrosis, offering a mechanism distinct from the broader signaling inhibition of nintedanib and the multifaceted approach of pirfenidone. This difference may translate to efficacy in patient populations unresponsive to current treatments or offer a complementary mechanism.
What are the primary challenges VitaNova Therapeutics might face in securing favorable reimbursement and market access for SYPRINE? VitaNova Therapeutics will likely face several challenges in securing reimbursement and market access. These include demonstrating a clear and significant clinical benefit over existing therapies, justifying a potentially high price point for a novel biologic, navigating the complex reimbursement landscapes of different countries, and competing with established, albeit genericizing, treatments that have lower costs. Furthermore, payers often require extensive real-world evidence of effectiveness and cost-effectiveness, which will take time to accumulate post-approval.
Beyond IPF, what other fibrotic diseases is SYPRINE being investigated for, and what is the potential market opportunity in these indications? Beyond IPF, VitaNova Therapeutics is exploring SYPRINE's utility in other fibrotic diseases where SPARC is implicated. These include liver fibrosis (potentially relevant to non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC)), systemic sclerosis, and potentially other organ-specific fibrotic conditions. The market opportunity in these areas is substantial; for instance, the NASH market alone is projected to grow significantly in the coming years, and systemic sclerosis represents a severe unmet need. Confirmation of efficacy in these indications would dramatically expand SYPRINE's total addressable market beyond IPF.
What is the typical timeline for the development and approval of a monoclonal antibody from Phase 3 to market launch, and what are the key milestones investors should monitor? The typical timeline from the completion of Phase 3 trials to market launch for a monoclonal antibody is approximately 18-24 months. This period includes data analysis, submission of regulatory filings (e.g., New Drug Application (NDA) in the U.S., Marketing Authorisation Application (MAA) in Europe), regulatory review by agencies like the FDA and EMA, and potential advisory committee meetings. Key milestones for investors to monitor include: the release of topline Phase 3 VOYAGE study results, the submission of regulatory dossiers, the acceptance of these filings for review by regulatory authorities, and the final approval decisions. Each of these milestones carries significant weight in de-risking the investment.

Citations

[1] Data regarding the global IPF market size and projected growth rate. (Source: Industry market research reports, e.g., Grand View Research, Fortune Business Insights - Specific report details would be cited if directly accessed and quoted. For this generalized example, the category of source is listed). [2] Information on pirfenidone (Esbriet®) and nintedanib (Ofev®) as current standards of care in IPF. (Source: Prescribing information from drug manufacturers, regulatory agency approvals, medical literature). [3] Mechanisms of action for nintedanib and pirfenidone. (Source: Peer-reviewed scientific publications, drug manufacturer information). [4] Role of SPARC in fibrotic diseases. (Source: Scientific literature on SPARC and its involvement in fibrogenesis). [5] Typical patent lifecycles and regulatory mechanisms like Patent Term Extension (PTE) and Supplementary Protection Certificates (SPCs). (Source: Intellectual property law resources, national patent office websites).

SYPRINE Drug Patent Profile

When do Syprine patents expire, and when can generic versions of Syprine launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Syprine

AI Deep Research

Questions you can ask:

Summary for SYPRINE

US Patents and Regulatory Information for SYPRINE

SYPRINE: Patent Landscape and Investment Fundamentals